021-51111890
购物车（）
sales@molnova.cn
CHF6001
CAS No. 1239278-59-1
CHF6001 ( CHF-6001;CHF 6001 )
产品货号. M10961 CAS No. 1239278-59-1
A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥5581 | 有现货 |
|
| 10MG | ￥7962 | 有现货 |
|
| 25MG | ￥11826 | 有现货 |
|
| 50MG | ￥15957 | 有现货 |
|
| 100MG | ￥21465 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CHF6001
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM.
-
产品描述A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM; inhibits PDE4 isoforms A-D with equal potency, 7- and 923-fold more potent than roflumilast and cilomilast, and displays >20,000-fold selectivity versus PDE4 compared with a panel of PDEs; effectively inhibits (subnanomolar IC50 values) the release of TNF-α from human PBMCs, THP-1, and rodent macrophages; inhibitsLPS-induced pulmonary neutrophilia (ED50=0.205 uM/kg) and leukocyte infiltration (ED50=0.188 uM/kg) in rats.COPD Phase 2 Clinical
-
同义词CHF-6001;CHF 6001
-
通路Angiogenesis
-
靶点PDE
-
受体PDE
-
研究领域Inflammation/Immunology
-
适应症COPD
化学信息
-
CAS Number1239278-59-1
-
分子量687.53
-
分子式C30H30Cl2F2N2O8S
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(O[C@H](C1=CC=C(OC(F)F)C(OCC2CC2)=C1)CC3=C(Cl)C=[N+]([O-])C=C3Cl)C4=CC=C(NS(=O)(C)=O)C(OCC5CC5)=C4
-
化学全称(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Armani E, et al. J Med Chem. 2014 Feb 13;57(3):793-816.
2. Villetti G, et al .J Pharmacol Exp Ther. 2015 Mar;352(3):568-78.
3. Moretto N, et al. J Pharmacol Exp Ther. 2015 Mar;352(3):559-67.
4. Edwards MR, et al. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00202.
2. Villetti G, et al .J Pharmacol Exp Ther. 2015 Mar;352(3):568-78.
3. Moretto N, et al. J Pharmacol Exp Ther. 2015 Mar;352(3):559-67.
4. Edwards MR, et al. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00202.
产品手册
关联产品
-
HA-155
HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.
-
Ro 20-1724
Ro20-1724 is a widely used inhibitor of cyclic nucleotide phosphodiesterase with IC50 of 2.0 μM and Ki of 3.1 μM.
-
Enoximone
Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.
